MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT (Time Zone - 9AM EST)
The end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy, Gene Therapy, Monoclonal Antibodies, Vaccines, biosimilars and biobetters, plasma therapy as well as others.
A host of attractive, high growth opportunities such as single use systems, Lab Scale and CGMP manufacturing and R&D, Crispr and other Gene editing tools and technologies, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs, CMOs, Bioprocess solutions manufacturers, Biobanks, automation technology providers etc can benefit from this unprecedented growth over the next 5 years.
This Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem, as seen through the lens of eminent CXOs in this space
Day 1 Thu, 11-Mar-2021
09:00 - 10:30
Top 10 disruptions in Biopharma Manufacturing
90 minutes of brainstorming among 4 great minds which will aim at bringing out a tangible action plan by discussing the question given below:
We are targeting speakers and Participants from potential companies like Merck KGA, Lonza, Bio-Rad Laboratories,Charles River Laboratories, MaxCyte, Becton, Dickinson & Co, FUJIFILM Irvine Scientific, bioMérieux,Foxx Life Sciences, InvivoGen, Patheon Inc, Cytovance Biologics, Greiner Bio-One, Cellexus, ABECK Group, G&G Technologies Inc etc.
Vice President & Head, US Marketing, Oncology & Immunology Biosimilars, Fresenius Kabi, USA
Global Head Cell Therapy, Strategy and Innovation, , Charles River Laboratories
Head of Commercial Division, Americas, GenScript ProBio
Executive Director - Business Development, Pall Corporation
Associate Director for Cell & Gene Therapy BioProcessing, MilliporeSigma